I attended the 2022 Madison Psychedelic Symposium organized by the University of Wisconsin Madison Transdisciplinary Center for Research in Psychoactive Substances on October 27th and 28th. There was a LOT of great information presented. Clinical trials with psilocybin for the treatment of Major Depressive Disorder and Treatment-Resistant Depression are going great! We should anticipate publication of the Phase 2b trial in the near future, and Usona Institute is planning for the Phase 3 trial early in 2023! Psilocybin-assisted therapy could begin in just three years or so! Things continue to look great for racemic ketamine infusions as well. They are being offered now at the VA hospital in Madison, as well as - at last count - 6 private clinics and the UW Hospital! As a side note, MAPS Public Benefit Corporation s expecting to apply to the FDA in just a few months for NDA (New Drug Application) for MDMA-assisted therapy for PTSD (Post-Traumatic Stress Disorder) in just several months from now! It is an optimistic time for those of us who suffer from mental health disorders, with new treatments on the foreseeable horizon!
Madison Psychedelic Symposium 2022
Updated: Oct 16, 2023
Commentaires